Last reviewed · How we verify
NCT04330833: IMPACT
Informational Meetings for Planning and Coordinating Treatment
NA trial testing Novel Communication Intervention in End of Life in 111 participants. Completed in 31 July 2025.
31 July 2025
Quick facts
| Lead sponsor | Indiana University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | supportive care |
| Enrollment | 111 |
| Start date | 8 December 2020 |
| Primary completion | 31 July 2025 |
| Estimated completion | 31 July 2025 |
| Sites | 7 locations across United States |
Drugs / interventions tested
- Novel Communication Intervention
- Enhanced Usual Care Parent Education
Conditions studied
- End of Life — all drugs for End of Life →
- Communication — all drugs for Communication →
- Cancer Metastatic — all drugs for Cancer Metastatic →
Sponsor
Indiana University
Who can join
Adults 1 Month to 17, any sex, with End of Life or Communication. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This prospective cluster-randomized trial examines the efficacy of a novel communication intervention delivered by trained physician and nurse dyads to parents of children with cancer within the clinicians' practice, to foster alignment of the goals of treatment. The investigators hypothesize that goal alignment will improve quality of life outcomes, in particular for those patients who reach end of life. Findings from the proposed research will provide essential information to promote communication practice standards that can be rapidly translated into practice to improve outcomes for children, particularly those who reach end of life, and parents.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Ensuring Intervention Fidelity of an Attention Control Arm in a Multisite Randomized Controlled Trial.
Newman AR, Moody KM, Becktell K, Connelly E, et al · · 2024 · PMID 38112626 · DOI 10.1097/nnr.0000000000000710
Verify or expand the search:
- PubMed search for NCT04330833
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for End of Life
Currently open trials in the same condition.
- NCT07147023 — Better Real-time Information on Documentation of Goals of Care for Engagement in Serious Illness Communication · NA · active not recruiting
- NCT06722352 — Palliative Care Education in Assisted Living for Dementia Care Providers (PCEAL-DCP) · NA · recruiting
- NCT07191184 — Identification of Obstacles and Levers to the Outpatient Care of Patients in Terminal Palliative Situations · recruiting
- NCT06071078 — Impact of a Protocol for Announcing Decision of Withholding and Withdrawing Life-sustaining Treatments on the Stress of · NA · recruiting
- NCT05861323 — Feasibility of the Comfort Measures Only Time Out (CMOT) · NA · active not recruiting
Other Indiana University trials
Trials by the same sponsor.
- NCT07470086 — The Role of Environmental Temperatures in Respiratory Control · NA · not yet recruiting
- NCT07470099 — The Role of Breathing Perception in Respiratory Control · NA · not yet recruiting
- NCT07179952 — Efficacy and Safety of Slow Release Dehydroepiandrosterone (DHEA ) · Phase 2 · not yet recruiting
- NCT07070804 — Maternal Biomarkers and Environmental Contributors to Autism Spectrum Disorders in Children of First-time Mothers · not yet recruiting
- NCT07499583 — Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04330833 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Indiana University
- Last refreshed: 8 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04330833.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing